A Phase 1 interventional study of REGEND001 in Idiopathic Pulmonary Fibrosis, sponsored by Regend Therapeutics. Completed at 3 sites in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-08.
Sponsored by Regend Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.
Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 54th largest by enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2021, is one of 20 in phase 1, and was the 25th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:
InSilico Medicine Hong Kong Limited · Sites in China
Ages 40+
AstraZeneca · Sites in China, United States, Argentina and 20 more countries
Ages 40+
Dragonboat Biopharmaceutical Company Limited · Sites in China
Ages 40+
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine · Sites in China
Ages 40–85
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 24 · Phase 3 14
First in 2012; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 83 across the 60 interventional studies, 310 across the 7 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 67 have an industry lead sponsor. The 10 most frequent:
Regend Therapeutics is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Regend Therapeutics has 3 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Idiopathic Pulmonary Fibrosis with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06125327Phase 3Guangzhou JOYO Pharma Co., LtdSC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | 2026-12-31 |
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT06267183Shanghai Synvida Biotechnology Co.,Ltd.A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. | 2026-11-30 |
| NCT07820254Shanghai Pulmonary Hospital, Shanghai, ChinaInspiratory Flow Rate Capability in Pulmonary Fibrosis Patients | 2026-12-31 |
| NCT07121413Shanghai Synvida Biotechnology Co.,Ltd.A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Idiopathic pulmonary fibrosis (IPF) is a condition where the lungs are damaged and scarred with unknown reason, making breathing becomes increasingly difficult.. REGEND001, made from airway basal cells with ability to regenerate lung tissue, is promising to IPF treatment. In this study, a single-armed clinical trial is ongoing to assess the safety and tolerability of REGEND001 in treatment of IPF. Different doses of REGEND001 is evaluated to establish a dose-response relationship and to suggest appropriate dose for subsequent clinical trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transplantation of autologous airway basal cells
Drug: REGEND001
Transplantation of REGEND001 for dose escalation.
Incidence and severity of the cell therapy-related adverse events (AEs)
Dose escalation is based on incidence of cell therapy-related AEs. Severity of cell therapy-related adverse events (AEs) is evaluated according to Common Terminology Criteria for Adverse Events (CTCAE).
Time frame: Within 24 weeks after treatment
Incidence of complication related to bronchoscopy
REGEND001 is given to subjects by bronchoscopy. Thus, incidence of complication related to bronchoscopy is adapted to assess the safety of the products.
Time frame: Within 24 weeks after treatment
Change in lung diffusing capacity for single-breath carbon monoxide (DLCO-sb) from baseline
DLCO-sb is measured by the single-breath method. It is considered a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.
Time frame: 4, 12 and 24 weeks after treatment
Change in forced vital capacity (FVC) from baseline
FVC indicates the volume of air that can forcibly be blown out after a full inspiration.
Time frame: 4, 12 and 24 weeks after treatment
Change in the ratio of diffusing capacity for carbon monoxide/ the alveolar volume (DLCO/VA) from baseline
The DLCO test refers to the diffusing capacity for carbon monoxide in the lungs. It is a type of pulmonary function test that helps to assess how well gas is exchanged between the lungs and the bloodstream. Since DLCO is affected by the amount of inhaled gas and lung volume, the alveolar ventilation is considered to exclude the effect of lung volume on diffusion volume in evaluating diffusion function.
Time frame: 4, 12 and 24 weeks after treatment
Change in 6-minute-walk test (6MWT) from baseline
The 6MWT is a commonly used test for the objective assessment of functional exercise capacity by testing the distance patients can walk at the fastest speed within 6 minutes.
Time frame: 4, 12 and 24 weeks after treatment
Change in St. George's Respiratory Questionnaire (SGRQ) scale from baseline
Quality of life was assessed by St. George's Respiratory Questionnaire (SGRQ) scale. Total score, ranged from 0 to 100, is the sum of points from all items. A higher value represents a worse outcome.
Time frame: 4, 12 and 24 weeks after treatment
Change in lung imags of high resolution computed tomography (HRCT) from baseline
Lung images from HRCT will be analyzed to indicate the newly-derived pulmonary structure.
Time frame: 24 weeks after treatment
Acute exacerbation of idiopathic pulmonary fibrosis (IPF)
Frequency and severity of acute exacerbation of IPF will be evaluated.
Time frame: Within 24 weeks after treatment
Change in blood routine from baseline
Number of cases or participants with abnormal laboratory test results will be evaluated.
Time frame: Within 24 weeks after treatment.
Change in urine routine from baseline
Number of cases or participants with abnormal laboratory test results will be evaluated.
Time frame: Within 24 weeks after treatment.
Change in blood biochemistry from baseline
Number of cases or participants with abnormal laboratory test results will be evaluated.
Time frame: Within 24 weeks after treatment
Change in 12-lead Electrocardiogram (ECG) from baseline
Number of cases or participants with abnormal results wil be evaluated
Time frame: Within 24 weeks after treatment
Change in carcinoembryonic antigen (CEA) from baseline
CEA is a tumor marker used for early diagnosis of lung cancer.
Time frame: 12 and 24 weeks after treatment
Change in neuron-specific enolase (NSE) from baseline
NSE is a tumor marker significantly elevated in small cell lung cancer.
Time frame: 12 and 24 weeks after treatment
Change in cytokeratin-19-fragment (CYFRA21-1) from baseline
CYFRA21-1 is a tumor marker which has important value for the pathological classification and prognosis evaluation of lung cancer.
Time frame: 12 and 24 weeks after treatment
Change in squamous cell carcinoma antigen (SCC) from baseline
SCC is a specific marker for lung squamous cell carcinoma. Tumor markers are monitored to assess the safety.
Time frame: 12 and 24 weeks after treatment
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Jun 2023, 22 months.
Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 22 months is above that.
Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: REGEND001
Idiopathic Pulmonary Fibrosis →
Regend Therapeutics